戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tions, such as outbreaks of yellow fever and meningococcal meningitis.
2 nd a substantial effect on confirmed group A meningococcal meningitis.
3  cohort studies comprising 373 patients with meningococcal meningitis.
4 fatality rate was 6-fold higher than that of meningococcal meningitis (28% vs 5%).
5 ally significant decline in risk of probable meningococcal meningitis across the age group targeted f
6           We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a s
7          We identified all reported cases of meningococcal meningitis and estimated the number of cas
8 o- or nasopharynx and the causative agent of meningococcal meningitis and meningococcemia, is capable
9 isseria meningitidis, the causative agent of meningococcal meningitis and septicemia, is an integral
10           Subsequently the patient developed meningococcal meningitis and was admitted to the neuroin
11                                 Epidemics of meningococcal meningitis are concentrated in sub-Saharan
12  incidence of suspected meningitis, probable meningococcal meningitis by age, and serogroup-specific
13                     Genomic surveillance for meningococcal meningitis can be significantly improved u
14 ecimens collected between 2017 and 2019 from meningococcal meningitis cases in 6 African countries.
15 a pneumococcal seroprevalence study during a meningococcal meningitis epidemic in Western Burkina Fas
16 is and carriage in Chad during a serogroup A meningococcal meningitis epidemic.
17                      After the major group A meningococcal meningitis epidemics in 1996-1997 (250,000
18            Because of initial concerns about meningococcal meningitis, families of day care attendees
19 nsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the
20 conjugate vaccine could help further control meningococcal meningitis in the region.
21                                              Meningococcal meningitis incidence was highest in the re
22        After the re-emergence of serogroup C meningococcal meningitis (MM) in Nigeria and Niger, we a
23                      No cases of serogroup A meningococcal meningitis occurred among vaccinated indiv
24 eningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing ra
25 her children identified with pneumococcal or meningococcal meningitis or children with a cerebrospina
26  These associations did not seem to apply to meningococcal meningitis or viral meningitis.
27 ACV has reduced serogroup A outbreaks, large meningococcal meningitis outbreaks due to other serogrou
28                                  Siblings of meningococcal meningitis patients also had lower educati
29                                 By contrast, meningococcal meningitis rates declined steadily, but re
30                                              Meningococcal meningitis remains a significant public he
31                                              Meningococcal meningitis remains a substantial cause of
32 s from 12 of 79 patients suspected of having meningococcal meningitis tested positive by both methods
33  a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be preven
34 al and H. influenzae meningitis, whereas for meningococcal meningitis the lower educational achieveme
35 nhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vacci